Business
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, representing a premium of 28% to the 30-day volume-weighted average trading price as of April 22, 2026The transaction marks Angelini Pharma's entry into the U.S. market, reinforcing its long-term commitment to Brain Health and its dedication to people living with Ra
About this update from Catalyst Pharmaceuticals, Inc.
[{"type":"image","alt":"Angelini Pharma; Catalyst Pharmaceuticals","displaySize":"","headline":null,"caption":"Angelini Pharma; Catalyst Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/48dcc145c5b9cbd1c537cc32539d70b7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jtyLednxHDUN9Npybeyisg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OA--/https://media.zenfs.com/en/globenewswire.com/48dcc145c5b9cbd1c537cc32539d70b7","width":300,"height":120},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/jtyLednxHDUN9Npybeyisg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OA--/https://media.zenfs.com/en/globenewswire.com/48dcc145c5b9cbd1c537cc32539d70b7","width":300,"height":120}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, representing a premium of 28% to the 30-day volume-weighted average trading price as of April 22, 2026","length":336,"tagName":"p"}]},{"val":[{"type":"text","content":"The transaction marks Angelini Pharma's entry into the U.S. market, reinforcing its long-term commitment to Brain Health and its dedication to people living with Rare Diseases ","length":179,"tagName":"p"}]},{"val":[{"type":"text","content":"Closing is expected in the third quarter of 2026","length":48,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":563,"olType":false},{"type":"text","content":"An earlier release was issued which has now been corrected.","length":59,"tagName":"p"},{"type":"text","content":"ROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A. (“Angelini Pharma”), an international pharmaceutical company and part of the Angelini Industries Group, and Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that they have entered into a definitive agreement pursuant to which Angelini Pharma has agreed to acquire all outstanding shares of Catalyst for 31.50 USD...